摘要
目的探讨帕罗西汀与氯米帕明治疗强迫症的效果及安全性比较。方法选择门诊或住院治疗的强迫症患者70例,采用随机数字表将患者分为帕罗西汀组和氯米帕明组。帕罗西汀组予以帕罗西汀片口服治疗,起始剂量20 mg/d,1周后根据病情可加至40 mg/d,最大剂量60 mg/d,连用12周。氯米帕明组予以氯米帕明片口服治疗,起始剂量50 mg/d,1周后根据病情可加至100 mg/d,最大剂量200 mg/d,早晚分2次服用,连用12周。观察并比较两组患者治疗后的临床效果及不良反应。结果治疗12周后,帕罗西汀组患者的治疗总有效率(86.11%)与氯米帕明组相近(79.41%)(χ2=0.55,P>0.05);帕罗西汀组患者治疗期间总的不良反应发生率(25.00%)明显低于氯米帕明组(52.94%)(χ2=5.76,P<0.05)。结论帕罗西汀与氯米帕明治疗强迫症均有较好的临床效果,两者的疗效相当,且帕罗西汀的不良反应较少,安全性较好,患者依从性较佳。
Objective To discuss the effect and safety of Paroxetine and Clomipramine on obsessive compulsive disor- der. Methods 70 cases of inpatients and outpatients with obsessive compulsive disorder were selected, and were ran- domly divided into Paroxetine group and Clomipramine group. The patients of Paroxetine group were given the initial dose of 20 mg/d with Paroxetine, it can be added to 40 mg/d according to the patient＇s condition after one week, the maximum dose was 60 mg/d. The patients of Clomipramine group were given the initial dose of 50 mg/d with Clomipramine, it can be added to 100 mg/d according to the patientJs condition after one week, the maximum dose was 200 mg/d （morning and evening taken twice）. All patients were treated for 12 weeks. The clinical curative effect and adverse reactions of patients in two groups before and after medical treatment were observed and compared. Results After 12 weeks, the final therapeutic effect in Paroxetine group （86.11%） was much similar with that in Clomipramine group （79.41%）, there was no significant difference between two groups （X2=0.55, P 〉 0.05）. The side effects in Paroxe- tine group （25.00%） was much lower than that in Clomipramine group （52.94%） （X2=5.76, P 〈 0.05）. Conclusion Both Paroxetine and Clomipramine have reliable and good effect on obsessive compulsive disorder. Their effect is not differ- ent. Paroxetine has less side effects, better safety and be easily accepted by patients.
出处
《中国医药导报》
CAS
2014年第3期89-91,共3页
China Medical Herald
关键词
强迫症
帕罗西汀
氯米帕明
疗效
安全性
Obsessive compulsive disorder
Paroxetine
Clomipramine
Curative effect
Security
